ArticleCureus2025
Fox-Fordyce Disease in Women: A Case Report Highlighting Laser-Based Interventions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fox-Fordyce disease (FFD) is a rare, chronic skin disorder affecting apocrine sweat glands, predominantly in women. It manifests as pruritic, dome-shaped papules in areas such as the axillae and pubic region. Treatment remains challenging, with limited success from conventional therapies. We report two cases of Saudi women aged 27 and 28 years presenting with hyperpigmented axillary papules and mild pruritus, consistent with FFD. One patient had no comorbidities, while the other had a known history of sickle cell anemia. Both cases were managed with laser therapy (erbium:yttrium aluminum garnet (YAG) in case 1 and ablative CO₂ in case 2) using precise protocols and follow-up plans. Clinical images demonstrated visual improvement post treatment. Adjunctive topical therapy was administered to manage inflammation and prevent hyperpigmentation. The cases underscore the typical presentation of FFD and the potential efficacy of laser-based interventions, even in patients with complex medical histories. Notably, the presence of sickle cell anemia did not exacerbate FFD manifestations, supporting the current treatment modalities. While hormonal therapy was not employed, its relevance remains a subject for future exploration. Laser therapy offers a promising approach for managing refractory FFD. Further studies are warranted to evaluate long-term outcomes and explore hormone-modulating strategies tailored to FFD's pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.